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Background: Switzerland introduced newborn screening (NBS) for CF in 2011, using an IRT/DNA/IRT protocol. This paper describes the results
of the ﬁrst year and compares two versions of the protocol with different IRT cut-offs, particularly effects on recall rate, sensitivity and speciﬁcity.
Methods: IRT cut-offs were N45 ng/ml (99.0th percentile) in period 1 (months 1–4) and N50 ng/ml (99.2nd percentile) in period 2 (months 5–12).
In period 2 we abstained from recalls when none of the 7 most common CF mutations were detected and IRT was b60 ng/ml.
Results: In periods 1 and 2, 26,535 and 56,663 tests were performed. Recall rates were 0.94% and 0.48%, respectively (p b 0.001), PPV increased
from 23% to 47% (p = 0.024) and sensitivity was 90% and 100%.
Conclusions: Raising initial IRT cut-off from the 99.0th to the 99.2nd percentile and abstaining from recalls for children with an IRT b 60 ng/ml
and carrying no major CFTR mutation signiﬁcantly reduced the recall rate without affecting sensitivity.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Newborn screening; Cystic ﬁbrosis; Immunoreactive trypsinogen; Recall rate1. Introduction
In Switzerland, newborn screening (NBS) was introduced in
1965 for the detection of Phenylketonuria, using a dried blood-
spot (Guthrie-test) on the 4th day of life. In the meantime,
five diseases were added to the NBS. Since 2006, NBS was☆ Part of this work has been presented at the 35th European Cystic Fibrosis
Conference in Dublin, Ireland, June 6–9, 2012 [21].
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http://dx.doi.org/10.1016/j.jcf.2013.04.008centralised and around 80,000 tests per year were performed by
the Swiss Newborn Screening Laboratory (SNSL). In January
2011, NBS for cystic fibrosis (CF) was introduced as a 2-year pilot
study, after conducting a retrospective study which confirmed that
the planned screening protocol with immunoreactive trypsinogen
(IRT) and the seven most common CF mutations in the Swiss
population would have detected all clinically diagnosed children
with classic CF in the years 2006–2009 included in this study
[1,2]. For the pilot study, we chose the 99th percentile for the
initial IRT cut-off as used in many NBS programmes [3,4].
Since the implementation of a new law on genetic testing in
Switzerland in 2007, written informed consent is mandatory for
genetic tests in the CF-centres; but not for the NBS [1]. After
delivery, all families get a brochure explaining NBS and the
currently screened diseases (www.neoscreening.ch); if they doby Elsevier B.V. All rights reserved.
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positive NBS result, the SNSL informs the nearest CF-centre,
which invites the child for further investigations. According to
the new law, the SNSL is not allowed to provide the CF-centres
with the exact genotype.
American and European guidelines for implementing NBS
for CF recommend careful evaluation of every country's
screening protocols to achieve optimum sensitivity and positive
predictive rates [5,6]. In the first year of the pilot study, we
therefore tested two subsequent versions of the protocol, using
each a different IRT cut-off (99th versus 99.2nd percentile) and
a different recall programme for a second heel-prick test. The
goal of this paper was to determine which protocol was most
effective. We compared recall rate, sensitivity, specificity,
positive predictive value (PPV) and negative predictive value
(NPV) between the first period (months 1–4; IRT: 99th
percentile) and the second period (months 5–12; IRT: 99.2nd
percentile).
2. Methods
2.1. General design of the Swiss CF-NBS
The protocol of the CF-NBS was divided into two parts: The
first part was the screening tests, performed by the Swiss
Newborn Screening Laboratory (SNSL) at the University
Children's Hospital in Zürich (see Investigations in the
SNSL). In the SNSL, the CF protocol begins with an initial
IRT measurement in a dried blood-spot, from a heel-prick
sample at the 4th day of life (see IRT measurement [1st tier]).
The blood-spots are sent by the birth clinics to the SNSL. A
genetic screening testing a limited number of mutations was
performed in the same blood-spot if initial IRT was above the
level of the cut-off (see CFTR mutation screening [2nd tier]). If
no mutation was found, a second heel-prick test was required to
repeat measurement of IRT. For this reason, the SNSL
informed the birth clinic, and they organized a second
heel-prick test by the midwife or the paediatrician two
weeks later. Children who were positive were referred to a
CF-centre if they had either an elevated level of initial IRT and
at least one CF mutation, or showed elevated IRT after two
screenings.
The second part of the screening protocol was diagnostic
evaluation of all children who had tested positive. These were
carried out in one of eight specialized Swiss paediatric CF-centres
(see Investigations in the CF-centres). All children referred to
CF-centres were given diagnostic sweat tests (see Sweat test). If
these were positive, borderline or inconclusive, another blood
sample was taken so that a detailed genetic analysis could be
performed in the genetic reference laboratory at the University of
Bern (see CFTR mutation analysis). In addition, faecal elastase
was measured to assess pancreas functionality at the time of the
sweat test.
To aid in determining the sensitivity of the newborn
screening protocols, all paediatric CF-centres agreed to report to
the study centre any new CF cases that were diagnosed outside
the screening programme.2.2. Investigations in the SNSL
2.2.1. IRT measurements (1st tier)
IRT is measured in dried blood spots using the GSP Neonatal
IRT-Kit (PerkinElmer Wallac, Turku, Finland) [7–9]. Analytical
sensitivity of the assay is approximately 3.0 ng/ml blood. Intra-
and inter-assay variation for the clinically relevant area is less
than 6%.
2.2.2. CFTR mutation screening (2nd tier)
The SNSL determined the seven most common CFTR
mutations in Switzerland with an in-house developed kit (SWISS
PANEL: F508del, 3905insT, G542X, R553X, W1282X, 1717-
1GNA, N1303K) [10,1]. For the first 4 months, the SNSL used
in addition to the in-house kit a commercial CFTR mutation kit
(LUMINEX xTAG® Cystic Fibrosis 39 kit v2, Luminex
Corporation, Austin, USA), which tested for 39 mutations, as it
was not guaranteed that the components of the in-house kit
would be available in the future.
LUMINEX is based on a Multiplex PCR amplification of
DNA, followed by fluorescent label incorporation using analyte
specific primer extension (ASPE). The ASPE product is
hybridized to beads. Results are returned by fully automated
process that uses software specifically designed for the task.
2.3. Investigations in the CF-centres
2.3.1. Sweat tests
Two sweat tests are performed simultaneously for each child,
using theMacroduct® and Nanoduct® systems. TheMacroduct®-
system uses pilocarpine iontophoretic stimulation (Webster
Sweat Collection System 3700-SYS, Wescor), followed by
sweat collection and sweat chloride concentration measurement
in the laboratory [11]. A minimum of 15 μl sweat is required
to determine chloride level. Sweat chloride of N60 mmol/l is
considered positive for CF; b30 mmol/l is normal [12]. Values
between 30 and 60 mmol/l were borderline and these children
were further assessed according to the current guidelines for
equivocal CF [13]. The Nanoduct®-system assesses conductivity
[14]. Its continuous sweat flow sensor requires only 3–5 μl of
sweat. Sweat conductivity is approximately 15 mmol/l higher
than sweat chloride, so a value of N80 mmol/l is consistent with
the diagnosis of CF; a value of b50 mmol/l is normal [14].
2.3.2. CFTR mutation analysis
The genetic reference laboratory at the University of Bern
performed diagnostic genetic testing. All parents provided
written informed consent for CFTR gene analysis. Genomic
DNA was extracted from peripheral blood cells using standard
procedures. In a first step, the laboratory tested for a panel of 32
mutations, using an in vitro diagnostic device (CF PCR-OLA
kit, v.3, Abbott AG) based on multiplex PCR amplification in
combination with an oligonucleotide ligation assay (OLA) that
produced allele-specific fluorescent labelled fragments, which
were separated by capillary electrophoresis. When the device
detected 0 to 1 mutation in a child, we proceeded to screen the
entire coding sequence of the CFTR gene, including intron/
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strand conformation polymorphism/heteroduplex technique, with
a sensitivity of 97–98% [15] followed by direct sequencing of
the variants (ABI 377 sequencing system, Applied Biosystems,
USA). Multiplex Ligation-dependent Probe Amplification
(SALSA MLPA probe mix P091-C1 CFTR-v07, MRC Holland)
was used to test for large deletions and duplications.
2.4. Detailed protocol of period 1 (months 1–4)
In the literature, the most widely used cut-off value for the IRT
is the 99th percentile (approximately 60 ng/ml) [4]. However, in
a test run using blood spots collected in December 2010 in
Switzerland, the cut-off for 99th percentile was 45 ng/ml [1]. We
therefore used a 45 ng/ml cut-off for the first period. For DNA
screening in the first period, we used both the SWISS PANEL
and LUMINEX assays in parallel (see CFTR mutation screening
(2nd tier)). Children with ≥1 detected CFTR mutation were
referred to a CF centre. We requested a second heel prick test for
a repeat IRT measurement for infants in whom CFTR mutation
was not detected. Infants whose second IRTwas N45 ng/ml were
also referred to a CF centre.
After 4 months, we examined initial and repeat IRT values,
and data from the genetic screening to assess the results (Tables 1
and 2). None of the CF cases had an initial IRT b 63 ng/ml.
None of the 15 children who had two elevated IRTs but no CFTR
mutation had classical CF. Based on these results, we adapted the
protocol for the second period in four different ways, described
below.
2.5. Detailed protocol of period 2 (months 5–12)
First, we increased the initial IRT cut-off from 45 ng/ml (99th
percentile) to 50 ng/ml (99.2nd percentile). Second, we decided
not to give a second heel prick test to children whose initial IRTTable 1
First year of CF-NBS in Switzerland: comparison of different outcome parameters b
Parameter Months 1–4
n
1st IRT above cut-off 250
At least one CFTR mutation detected 24
Recall rate for 2nd heel prick test (2nd IRT measurement) 226
Overall recall rate (2nd heel prick test and referral to CF centre) 250
Referrals to CF-centre 39
Classic CF 7
Equivocal CF 2
Sensitivity (all CF) 9
Specificity (all CF) 26,495
Positive predictive value all CF (based on recall) 9
Positive predictive value all CF (based on referral) 9
Positive predictive value only classic CF (based on recall) 7
Positive predictive value only classic CF (based on referral) 7
Negative predictive value 26,495
Abbreviations: CF, Cystic Fibrosis; CFTR, Cystic Fibrosis Transmembrane Conduc
a p-Value calculated from two-sample proportion test.
b Including one clinically diagnosed child with meconium ileus (IRT 39.5 ng/ml)was b60 ng/ml and who had no SWISS PANELmutation. Third,
we stopped using the LUMINEX kit for genetic screening.
Fourth, in children with meconium ileus (MI), CFTR mutation
screening was always performed irrespective of the IRT value.
2.6. Statistical analysis
We described the results of the screening and the diagnostic
evaluation for all children referred to a CF centre during the two
periods. Then we calculated the effectiveness of the screening
tests for the first and second periods, comparing recall rate,
sensitivity, specificity, PPV and NPV. Finally, we made a
frequency distribution of the initial IRT values of all newborns
in 2011, to see the effect of the different cut-off levels.
3. Results
3.1. Period 1 (months 1–4)
Between January and April 2011, 26,535 IRT tests were
performed; 250 (0.94%) samples had values N 45 ng/ml and
led to DNA screening (Fig. 1, Table 1). Twenty-four children,
with one or two mutations, were directly referred to a
CF-centre. In 226 children, IRT was measured again by a
second heel prick (recall rate = 0.85%). In 15 of these children,
IRT was still N45 ng/ml and they were referred to a CF centre.
One child (case No. 7, Table 2) was referred to the CF centre
despite a second IRT value of b45 ng/ml (43.6 ng/ml) because
we were cautious in the early phase of screening and the
decrease in IRT after the second test was small. Of the 24
children directly referred, 20 had≥1 SWISS PANEL mutation,
and four had a mutation detected only by the LUMINEX test
(Table 2).
In total, 39 children were examined in a CF centre (referral
rate = 0.15%) at a median time of 30 days (range: 12–151). Inetween period 1 (months 1–4) and period 2 (months 5–12).
(N = 26,535) Months 5–12 (N = 56,663)
N % n N % p-Value a
26,535 0.94 397 56,663 0.70 b0.001
250 9.60 41 397 10.33 0.157
26,535 0.85 230 56,663 0.41 b0.001
26,535 0.94 271 56,663 0.48 b0.001
26,535 0.14 45 56,663 0.08 0.002
26,535 0.03 20 56,663 0.04 0.499
26,535 b0.01 1 56,663 b0.01 0.203
10 b 90.00 21 21 100.00 0.141
26,525 99.89 56,618 56,642 99.96 b0.001
250 3.60 21 397 7.75 0.042
39 23.08 21 45 46.67 0.024
250 2.80 20 397 5.04 0.172
39 17.94 20 45 44.44 0.005
26,496 99.99 56,618 56,618 100.00 0.017
tance Regulator; IRT, Immunoreactive Trypsinogen.
.
Table 2
Characteristics of all children, who were referred to a CF centre for diagnostic testing within 4 months (n = 40).
Case no GA
(weeks)
Weight
at birth
(g)
1st IRT
(4th day
of life)
(ng/ml)
2nd IRT
(repeat heel
prick)
(ng/ml) a
CFTR mutation
screening SWISS
PANEL in NBS
laboratory b
CFTR mutation
screening LUMINEX
in NBS laboratory b
CFTR mutation
diagnosis in genetic
reference laboratory c
Sweat chloride
macroduct
method
(mmol/l) d
Sweat
conductivity
nanoduct method
(mmol/l) d
Pancreas
function faecal
elastase
(ng) e
Diagnosis
1 39 2980 183.0 F508del/– F508del/– F508del/420del9 97 113 45 CF
4 39 3290 150.2 F508del/F508del F508del/F508del F508del/F508del – 129 23 CF
11 37 3400 270.0 F508del/– F508del/– F508del/2347delG 105 98 b15 CF
14 40 3655 114.4 F508del/F508del F508del/F508del F508del/F508del – 116 37 CF
21 37 3280 119.5 F508del/F508del F508del/F508del F508del/F508del ND ND b15 CF with MI
23 f 38 2900 76.9 F508del/F508del F508del/F508del F508del/F508del ND ND b15 CF
35 37 2930 134.8 F508del/– F508del/621+1GNT F508del/621+1GNT 110 139 b15 CF
40 37 2980 39.5 41.8 F508del/F508del F508del/F508del F508del/F508del – 97 b15 CF with MI
12 41 3810 65.9 –/– R347P/– R347P/4006-46del5 h 38 37 ND i Equivocal CF
20 g 38 2720 63.0 122.9 –/– –/– T5/T1086A h 35 – 382 Equivocal CF
2 41 3250 50.1 F508del/– F508del/– – 39 No CF
10 38 2590 51.3 F508del/– F508del/– 14 47 No CF
13 39 3330 68.8 F508del/– F508del/– 11 36 No CF
17 39 2670 64.1 1717-1GNA/– 1717-1GNA/– 20 15 No CF
18 40 3360 58.9 3905insT/– 3905insT/– 13 36 No CF
22 38 2970 51.3 F508del/– F508del/– – 27 No CF
24 36 2790 49.1 F508del/– F508del/– 10 48 No CF
27 40 3420 60.7 F508del/– F508del/– 6 23 No CF
31 40 4400 55.5 F508del/– F508del/– 14 29 No CF
32 41 4460 89.5 F508del/– F508del/– 14 33 No CF
33 40 3700 130.6 F508del/– F508del/– ND 36 No CF
34 40 3005 65.4 N1303K/– N1303K/– 24 37 No CF
36 39 2780 61.5 F508del/– F508del/– F508del/– d ND – No CF
15 40 3310 49.3 –/– R347H/– 10 39 No CF
16 37 3240 56.0 –/– R347H/– 18 54 No CF
29 34 1870 126.5 –/– 2184delA/– 2184delA/– – – No CF
3 41 3860 46.2 72.6 –/– –/– 13 44 No CF
5 37 2840 60.1 61.0 –/– –/– – 51/34 No CF
6 40 3030 56.6 56.2 –/– –/– 16 34 No CF
7 37 3130 49.0 43.6 –/– –/– 6 18 No CF
8 39 4320 48.7 94.9 –/– –/– 13 27 No CF
9 37 2050 127.9 52.3 –/– –/– 28 28 No CF
19 38 3570 68.1 54.5 –/– –/– 6 45 No CF
25 35 2300 61.5 50.2 –/– –/– 12 37 No CF
26 40 2780 58.2 59.8 –/– –/– 10 48 No CF
28 40 3430 56.5 53.4 –/– –/– 13 31 No CF
30 37 2930 54.2 65.6 –/– –/– – 32 No CF
37 40 3615 65.9 191.4 –/– –/– ND 51 No CF
38 41 4350 56.2 65.1 –/– –/– ND 41 No CF
39 42 2900 51.6 68.5 –/– –/– 20 – No CF
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2nd IRT 
measurement
211 
negative
226 without mutation (90%) 
Recall rate for 2nd heel prick = 0.85% 
7 classic CF 
2 equivocal CF 
30 without CF diagnosis
DNA 
screening
24 with 1 or 2 CFTR 
mutations                             
(9.6% of 250)
15 (6.6% of 226) positive 
(IRT>45ng/ml)
250 (0.94%) positive 
(IRT>45ng/ml)
January to April 2011 May to December  2011
1st IRT 
measurement
26'285 
negative
26'535 IRT-analyses 
in dried blood spots
39 referrals 
to CF-centres 
(0.15% of 26’535)
2nd IRT 
measurement
226 
negative
230 without mutation (57.9%) 
Recall rate for 2nd heel prick = 0.41% 
20 classic CF 
1 equivocal CF 
24 without CF diagnosis
DNA 
screening
41 with 1 or 2 CFTR 
mutations (10.3%)
4 (1.7% of 230) positive 
(IRT>50ng/ml)
397 (0.70%) positive 
(IRT>50ng/ml)
1st IRT 
measurement
56’266 
negative
56’663 IRT-analyses 
in dried blood spots
45 referrals 
to CF-centres                  
(0.08% of 56’663)
126 without mutation but 
with 1st IRT <60ng/ml
Fig. 1. Evaluation of the first year of the CF newborn screening in Switzerland. Abbreviations: CF, Cystic Fibrosis; CFTR, Cystic Fibrosis Transmembrane
Conductance Regulator; DNA, Deoxyribonucleic Acid; IRT, Immunoreactive Trypsinogen; PPV, Positive Predictive Value.
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test and/or two CFTR mutations (PPV = 23.1%; Table 1).
Seven children had a classic CF carrying at least one of the
SWISS PANEL mutations; four were homozygous, and three
were heterozygous for F508del. Two children carrying one
CFTR mutation not associated with classic CF (equivocal CF)
were both pancreatic-sufficient and asymptomatic by age one
year (case Nos. 12 and 20, Table 2).
All seven children with classic CF and the two children
diagnosed with equivocal CF had an initial IRT value of
N60 ng/ml (range: 63–270 ng/ml, Table 2). All 14 children
with initial and repeat IRT between 45 and 60 ng/ml, but no
SWISS PANEL mutation, had normal sweat tests or no CFTR
mutations after extended gene analysis. One false negative IRT
result was detected in a child clinically diagnosed because of a
MI. This child was homozygous for F508del, but had a normal
IRT (39.5 ng/ml, case No. 40, Table 2).Notes to Table 2:
Abbreviations: CF, cystic fibrosis; CFTR, Cystic Fibrosis Transmembrane Conduc
Meconium Ileus; mts, months; NBS, Newborn Screening; ND, not done; No, Numb
a No 2nd IRT test was done in children where at least one CFTR mutation was d
b A dash in the columns of the genetic analyses means that the investigation was
c CFTR mutation diagnosis was only done in children with positive, not valid or
d A dash in the columns of the sweat tests means that the test was attempted but
e Faecal elastasewas determined in childrenwith CF or equivocal CF at the first assessm
f This child had also a Trisomy 21 and an atrium septum defect (ASD) and was o
g This child had also a complex heart disease and renal insufficiency.
h This CFTR mutation is so far not described as CF-causing mutation.
i The parents refused to determine the faecal elastase, but the stool quality and th3.2. Period 2 (months 5–12)
In the second period, 56,663 IRT tests were performed and
397 (0.70%) were N50 ng/ml (Fig. 1, Table 1). In 41 of these
children, at least one SWISS PANEL mutation was detected.
Of the remaining 356, 126 had an initial IRT b 60 ng/ml.
Therefore, a second IRT test was performed for only 230
children, leading to a decreased recall rate for a second heel
prick test by 52% (0.85% vs. 0.41%). Of the 230 children, only
four had an elevated repeat IRT and were referred to a CF
centre. One of these four children was diagnosed with CF
(heterozygous 711+5GNA/3659delC, sweat chloride 82 mmol/l,
pancreas-insufficient, initial IRT 207 ng/ml); the other three
were healthy. The CF centres have so far found no children
with CF who were not detected by the screening procedure
(with an initial IRT b 50 ng/ml). Of the 45 children referred
(referral rate 0.08% compared to 0.15% in period 1), 20 weretance Regulator; GA, Gestation Age; IRT, Immunoreactive Trypsinogen; MI,
er.
etected in the screening.
done but no CFTR mutation was detected.
inconclusive sweat test.
the result was not valid (not enough sweat, technical problems).
ent. If it was normal (N200 ng), themeasurement was repeated in the first year of life.
n the intensive care unit because of a neonatal respiratory distress syndrome.
e child's growth were normal after one year of life.
672 T. Torresani et al. / Journal of Cystic Fibrosis 12 (2013) 667–674diagnosed with CF and the genotype of one child met the criteria
of equivocal CF (Table 1, Online-Table 3). This corresponds to a
PPV of 47%, compared to 23% in the first period. All children
were seen in the CF centre at the median time of 22 days (range:
4–314). In period 2, we had 5 children with MI; 4 had an
IRT N 50 ng/ml (range: 77.7–102.3), and one below the 99.2nd
percentile (42.9 ng/ml).
4. Discussion
Two changes to the initial protocol (increasing the initial IRT
cut-off from 45 to 50 ng/ml and abstaining from a second IRT
test if the initial IRT was b60 ng/ml) significantly cut down
recalls without reducing sensitivity (e.g. missing a child with CF).
Because the goal of an NBS is not only to detect as many cases as
possible, but also to minimize false positive results, these results
are important. Initial IRT cut-off has a powerful effect on the
effectiveness of NBS, determining the sensitivity and specificity
of a programme [5]. Proper adjustment of the initial IRT cut-off
addresses the following problems.
False positive results and second heel prick tests pose a
challenge to NBS programmes as they bring families to un-
necessary medicalization. In addition, when non-affected chil-
drenwith elevated IRT are tested in a CF centre, their parents may
feel anxious or depressed while awaiting definitive results [16].
In a minority of cases, parental anxiety may persist for some time,
despite subsequent negative sweat test results [17]. Thus we
wished to minimize false positives and unnecessary recalls, while
preserving diagnostic sensitivity through close monitoring of the
implementation of the CF-NBS. A recall rate of 0.85% for a
second heel prick test within the first four months prompted us to
reassess our strategy and optimize initial IRT cut-off.
In the first period, no child with an initial IRT of b60 ng/ml
had CF (Fig. 2). Because the evaluation period (four months) wasFig. 2. Frequency distribution of initial IRT values in 2011. Abbrevishort, we were conservative and chose the cut-off of 50 ng/ml
(99.2nd percentile) rather than 60 ng/ml (99.5th percentile). In
fact, in the second period we did detect one CF case with an IRT
of 59 ng/ml. By increasing the cut-off for genetic testing to
50 ng/ml, and abstaining from a second IRT test if the initial IRT
was b60 ng/ml, we lowered recall rate for a second heel prick test
by 52% (0.85 vs. 0.41; p b 0.001; Table 1), specificity increased
from 99.89% to 99.96% (p b 0.001), and the PPV improved
from 23% to 47% (p = 0.024). In the second period, only 4
children with persistently elevated IRTs but no CFTR-mutation
were referred to a CF centre. One of these was diagnosed with CF
with two rare CF mutations in Switzerland. This child had an
initial IRT of 207 ng/ml (N99.9th percentile; Fig. 2).
Safety net strategies for NBS programmes are currently
debated. The Australian experience of CF-NBS demonstrated
that additional CF testing for infants with an elevated IRT but
no CFTR mutation has an extremely low yield, regardless of
the IRT level [18]. To ensure that we do not miss children with
CF carrying mutations uncommon in Switzerland, we initially
performed a second IRT in all infants with elevated initial IRT
where no CFTR mutation was detected. After 4 months, we
developed a safety net (Fig. 3), in which only children with an
elevated IRT N 60 ng/ml but without any CFTRmutation receive
a second IRT measurement. In period 2 of our study, one out of
four children, whowas referred to a CF centre because of a second
elevated IRT (1/230 = 0.4%, Fig. 1), had a classic CF. At the end
of the two-year pilot, we will decide whether to continue to recall
children who have an elevated IRT N 60 ng/ml but no CFTR
mutation or increasing the IRT threshold that triggers a second
IRT in order to further reduce a second heel prick test. A possible
alternative is to change our protocol and create a different safety
net; e.g., refer all children with an IRT N 99.9th percentile
whether or not a CFTR mutation is detected. This would enable
infants to avoid a second heel prick test.>140
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Fig. 3. New algorithm of CF newborn screening in Switzerland since May 2011. Abbreviations: CF, Cystic Fibrosis; CFTR, Cystic Fibrosis Transmembrane
Conductance Regulator; IRT, Immunoreactive Trypsinogen; NBS, Newborn Screening.
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results. The screening programmes from Australia have a false
negative rate of up to 8%, and up to 25% of infants with MI
have a normal IRT [3,8,19,20]. Therefore, high risk infants
such as newborns with MI and sibling with CF should always
have a sweat test, regardless of the screening results [19]. In the
first four months, there were two infants with CF and MI, but
only one was detected by our screening protocol. This explains
the sensitivity of 90% in the first period. We then adapted our
protocol and used direct CFTR mutation screening in all children
with MI irrespective of the IRT value (Fig. 3), and we had no
further false negatives. However, final evaluation of sensitivity
takes years because children with mild CF develop symptoms
only later in life.
The strength of this study is our careful documentation of
the results of each step of the CF-NBS. We analysed the results
of each screening step in detail and thoroughly documented the
effects of changes to the protocol. Involvement of all Swiss CF
centres and independent assessment of clinically diagnosed CF
cases allowed us to carefully monitor sensitivity. However, the
duration of the two periods was relatively short; this limited
statistical power. During the first period, 39 children were
referred to a CF-centre and only seven were diagnosed with
classical CF. These are low numbers as basis for adapting the
protocol. Continuous monitoring over the next years will allow
us to make more precise estimates and derive more robust
conclusions.
In conclusion, changes in the protocol implemented during
the first year of the Swiss NBS for CF resulted in significantly
fewer recalls and higher PPV, without a loss in sensitivity.
A small protocol change, even after a short period, can haveprofound impact on the performance of a programme reducing
the unnecessary medicalization of a large number of families
and the negative impacts this has on their well-being. This
study highlights that NBS needs to be monitored closely and
programmes need to be responsive to the results and not accept
high levels of recall and sweat testing.
Supplementary data to this article can be found online at
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